SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Vincent van Gogh — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientVincent van Gogh
Date of birth1853-03-30
IdentifiersMRN HR-NI010-SYN-TD; SSN (made up) 000-10-3198
Document date1889-03-02
AuthorElise Verhoeven, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week review: symptoms, side effects, alcohol, sleep, and test results. [S]

History of Present Illness

Mr. van Gogh returns six weeks after his first visit and two weeks after the sick visit for akathisia, when aripiprazole went back to 10 mg and propranolol was started. The restlessness eased within three days and has been gone for more than a week. The night-time voices have not returned on 10 mg. He sleeps six and a half to seven hours. He is painting again for a few hours most days, which he says matters more to him than anything. He takes naltrexone daily and now has one or two glasses of wine on most evenings; he notices that he wants a second glass less. His mood is better, and the thoughts of not waking up have stopped. He meets the care coordinator weekly and has seen the therapist twice. [S]

ElementDetail
Aripiprazole10 mg daily for two weeks, every dose taken
AkathisiaResolved within three days; propranolol 10 mg twice daily
Psychotic symptomsNone
SleepSix and a half to seven hours
AlcoholOne or two glasses of wine most evenings
MoodBetter; PHQ-9 8; item 9 scored 0

Review of Systems

SystemResultFinding
NeurologicalNegativeNo restlessness, stiffness, tremor, seizures, or lost time
CardiovascularNegativeNo dizziness or fainting on propranolol
GastrointestinalNegativeMild nausea in the first days of naltrexone, now gone
PsychiatricNegativeNo voices or suspiciousness; mood improving; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aripiprazole 10 mg oral tablet, one tablet by mouth once daily (started in hospital)One tablet by mouth once dailyOral route1889-01-05 to 1889-02-02completedS
Aripiprazole 15 mg oral tablet, one tablet by mouth once dailyOne tablet by mouth once dailyOral route1889-02-02 to 1889-02-16completedS
Naltrexone 50 mg oral tablet, one tablet by mouth once dailyOne tablet by mouth once dailyOral route1889-02-02activeS
Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital)One tablet by mouth dailyOral route1889-01-05 to 1889-07-20completedS
Aripiprazole 10 mg oral tablet, one tablet by mouth once dailyOne tablet by mouth once dailyOral route1889-02-16activeS
Propranolol 10 mg oral tablet, one tablet by mouth twice daily for akathisiaOne tablet by mouth twice dailyOral route1889-02-16 to 1889-03-02completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1889-03-02Body height170cmS
1889-03-02Body weight64.9kgS
1889-03-02Body mass index (BMI) [Ratio]22.5kg/m2S
1889-03-02Systolic blood pressure120mm[Hg]S
1889-03-02Diastolic blood pressure76mm[Hg]S
1889-03-02Heart rate76/minS
1889-03-02Respiratory rate14/minS
1889-03-02Body temperature36.6CelS
1889-03-02Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1889-03-02Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma41U/L10-40 U/LHighS
1889-03-02Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma37U/L7-56 U/LNormalS
1889-03-02Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma68U/L8-61 U/LHighS
1889-03-02Phosphatidylethanol [Mass/volume] in Blood122ng/mLBelow 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinkingHighS
1889-03-02Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S

Physical Exam

Vital signs recorded on 1889-03-02; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 64.9 kg; blood pressure 120/76, pulse 76
NeurologicalNo akathisia (Barnes global rating 0), rigidity, tremor, or abnormal movements
PsychiatricBrighter affect; organized; no psychotic features; insight good

Problems

ProblemClinical statusVerificationCodeProvenance
First episode of psychosis with mood features: weeks of very little sleep, intense work and expansive plans, then acute confusion, hallucinations and suspiciousness with self-injury, and low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, brief psychotic or schizophreniform disorder, alcohol withdrawal delirium or alcohol-induced psychotic disorder, and psychosis related to focal epilepsy. Synthetic modern episode linked to his documented first crisisactiveprovisional F29S — Synthetic modern coding of the documented first crisis. Unspecified psychosis is coded because the cause is not yet established; the retrospective diagnoses stay in the claims.
Alcohol use disorder, moderate (heavy daily wine and anise spirits before the episode); synthetic modern episode linked to his documented heavy drinkingactiveconfirmed F10.20S — Synthetic modern coding of the documented drinking and its retrospective interpretation.
Self-injury to the left ear during the acute confusional episode, without suicidal intent; wound healed after surgical care in hospitalactiveconfirmed Z91.52S — Synthetic modern coding of the documented injury; no detail of the injury is recorded.
Akathisia from aripiprazole, two weeks after the dose was increased to 15 mg; treated by returning to 10 mg and short-term propranolol; resolvedresolvedconfirmed G25.71S — Synthetic medication side effect; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyAntipsychotic dose, adherence, and responseEvery visitCompleted todayAripiprazole 10 mg since the sick visit; full adherence; remission of psychotic symptoms
SurveyPsychotic and mood symptoms, and early warning signsEvery visitCompleted todayNo hallucinations or suspiciousness; no early warning signs
ExaminationAkathisia, parkinsonism, and sedationEvery visit in the first months and after any dose changeCompleted todayAkathisia resolved; no parkinsonism or sedation; propranolol stopped
ExaminationWeight and BMIEvery visit for 6 months after starting, then quarterly (CMID: baseline, 4, 8, and 12 weeks, then quarterly)Completed today64.9 kg at eight weeks, from 64.0
ExaminationBlood pressureBaseline, 12 weeks, then yearlyCompleted today120/76
LaboratoryFasting glucose and A1cBaseline, 12 weeks to 4 months, then yearlyUp to dateNext at the three-month visit
LaboratoryFasting lipid panelBaseline, 12 weeks to 4 months, then yearlyUp to dateNext at the three-month visit
LaboratoryFirst-episode workup (MRI and EEG)Once, in the first-episode workupCompleted todayBrain MRI normal; sleep-deprived EEG without epileptiform discharges
SurveyDepression measure (PHQ-9)Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodicallyCompleted todayPHQ-9 8, item 9 scored 0
SurveySuicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; safety plan current; the 988 Suicide & Crisis Lifeline in his phone
Self-managementSleepEvery visitCompleted todaySix and a half to seven hours at regular times
SurveyDrinking (AUDIT-C and PEth)PEth at intake and at each check while drinking continues; AUDIT-C yearlyCompleted todayPEth 122 ng/mL, from 284
Medication safetyNaltrexone: liver tests and opioid exposureLiver tests before starting, then at 1 to 3 months and every 6 to 12 monthsCompleted todayAST 41, ALT 37, GGT 68 U/L, improving; no opioid use
Medication safetyThiamineWhile drinking heavilyCompleted todayTaking thiamine daily
Self-managementCoordinated specialty care engagementOngoing, for up to two to three yearsCompleted todayCare coordinator weekly; therapist twice; peer specialist introduced

Goal progress:

Guideline basis: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Three-month visit with fasting glucose, A1c, lipids, liver tests, PEth, and the PHQ-9. Care coordinator weekly; therapist every two weeks. Next scheduled visit 1889-04-20: three-month review with the 12-week metabolic check. [S]